High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019

Wei Cao, Xiaosheng Liu, Tao Bai, Hongwei Fan, Ke Hong, Hui Song, Yang Han, Ling Lin, Lianguo Ruan, Taisheng Li, Wei Cao, Xiaosheng Liu, Tao Bai, Hongwei Fan, Ke Hong, Hui Song, Yang Han, Ling Lin, Lianguo Ruan, Taisheng Li

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with COVID-19.

Keywords: coronavirus disease 2019; high-dose intravenous immunoglobulin; immunomodulation.

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Chest computed tomography scan of patient 1 (A), patient 2 (B), and patient 3 (C) before and after high-dose intravenous immunoglobulin with days of illness.

References

    1. Real-time updates: national outbreak map of new coronary virus pneumonia Available at: . Accessed 12 March 2020.
    1. National Health Commission of the People’s Republic of China. Chinese recommendations for diagnosis and treatment of novel coronavirus (SARS-CoV2) infection (pilot 4th version). Available at: . Accessed 12 March 2020.
    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506.
    1. Zhu N, Zhang D, Wang W, et al. . A novel coronavirus from patients with pneumonia in China, 2019. New Engl J Med 2020; 382:727–33.
    1. Chung M, Bernheim A, Mei X, et al. . CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 2020; 295:202–07.
    1. Patwa HS, Chaudhry V, Katzberg H, et al. . Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009–15.
    1. Godeau B, Caulier MT, Decuypere L, et al. . Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol 1999; 107:716–9.
    1. Lu R, Zhao X, Li J, et al. . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395:565–74.
    1. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. In press.
    1. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. In press.
    1. Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol 2017; 29:491–8.
    1. De Ranieri D, Fenny NS. Intravenous immunoglobulin in the treatment of primary immunodeficiency diseases. Pediatr Ann 2017; 46:e8–e12.
    1. Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008; 255(Suppl 3):3–6.
    1. Wiedeman AE, Santer DM, Yan W, et al. . Contrasting mechanisms of interferon-α inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists. Arthritis Rheum 2013; 65:2713–23.
    1. Khanna N, Widmer AF, Decker M, et al. . Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 46:402–12.
    1. Wang JT, Sheng WH, Fang CT, et al. . Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 2004; 10:818–24.
    1. Arabi YM, Arifi AA, Balkhy HH, et al. . Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014; 160:389–97.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel